IMPROVED PATIENT OUTCOMES USING PLERIXAFOR WITH G-CSF TO IMPROVE STEM CELL MOBILIZATION

Ghazala S. Nathu*

ABSTRACT

Autologous hematopoietic stem cell (HSC) transplantation is a crucial treatment for patients undergoing high-dose chemotherapy for conditions such as Hodgkin’s disease, non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM), leukemias, and certain solid tumors. Successful transplantation depends on the ability to collect an adequate number of CD34+ HSCs from the peripheral blood, a process that can be challenging for some patients using standard mobilization methods like chemotherapy and granulocyte colony-stimulating factor (G-CSF Plerixafor, an FDA-approved agent used in combination with G-CSF, has significantly improved stem cell mobilization, particularly in patients with lymphoma and myeloma who struggle to mobilize sufficient cells. Its introduction has expanded the number of patients eligible for transplantation, reducing the need for multiple apheresis sessions and improving collection efficiency. However, due to its high cost, plerixafor is typically reserved for patients who fail standard mobilization strategies. Ongoing research continues to explore its broader applications, including its potential use in allogeneic transplantation and other hematologic conditions. As the role of plerixafor in stem cell therapy evolves, its impact on transplantation success and patient outcomes remains an important area of study.

Keywords: .